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Editors under Pressure—
Avoiding Conflicts
Editors would like to imagine they are
simply gatekeepers who facilitate the
interaction between authors who wish to
impart information and people who want
to read it. In fact, they are subject to a raft
of external pressures that interfere with
this core task. Coauthors are prone to
disputes with each other and with review-
ers; rejected authors may protest; readers
may be dissatisfied; institutions may react
inadequately to editors’ concerns about
probity; editorial freedom may be com-
promised by the demands of the learned
society that owns the journal; and a
commercial publisher might exert sub-
tle—or unsubtle—pressure to increase
profitability. All of these distractions in-
crease the possibility of competing inter-
ests corrupting the editorial process.
Influence of the Impact Factor
Added to this toxic mixture is the
impact factor (IF). Just as many clinicians
claim that contacts by pharmaceutical
company representatives do not affect
their prescribing behaviour, so editors
are likely to deny that thoughts of a rising
IF might influence their acceptance rates.
In their paper published this week in PLoS
Medicine, Andreas Lundh and colleagues
analysed randomised controlled trials pub-
lished in six high-impact general medical
journals during two time periods a decade
apart; they calculated the putative fall in
IF that would have occurred had publica-
tion been denied to papers that were
commercially sponsored [1].
Unsurprisingly, they found the expected
association, since IF depends in turn on
recent citation rates, and a body of
literature shows that industry-sponsored
trials attract more citations than those
funded by a nonprofit source [2,3]. There
are reasons: for example, randomised
controlled trials and meta-analyses are
cited more frequently than clinical studies
with less-rigorous design, regardless of
funding, and high-impact journals are
likely to attract the former [4]. There is
‘‘gamesmanship,’’ with commercial spon-
sors and publishing companies skilled at
obtaining publicity in the mass media, a
known stimulant for citations [5,6]. Only
slightly dubious is the habit of commercial
companies disseminating papers favour-
able to their product to individual clini-
cians at conferences or through sponsor-
ship of review papers—themselves a
potent accelerator of IF [7]. More culpa-
ble is the fact that studies showing positive
outcomes for a drug or device under
consideration are more likely to be pub-
lished than ‘‘negative’’ studies; editors are
partly to blame for this but so are
commercial sponsors, whose methodolog-
ically well-conducted studies with unfa-
vourable results tended not to see the light
of day, at least in the pretrial registration
era [8].
Lundh and colleagues do not claim that
their findings demonstrate that editors’
judgment on acceptance or rejection is
influenced by the paper’s predicted effect
on IF. Nonetheless, I have heard editors
support a paper at a selection meeting by
stating that it is likely to be well cited.
Publishers’ Profits and
Sponsored Studies
More intriguingly, the second aim of
their study was to investigate the possible
financial benefits to publishers of the
journals they investigated. Their attempt-
ed method was to seek data on income
from advertisements, reprints, and indus-
try-supported supplements as a percentage
of total income. The editors of the two
UK-based journals, BMJ and The Lancet,
provided the data. The editors of JAMA
and The New England Journal of Medicine
(NEJM) declined, as did the publisher of
Annals of Internal Medicine. The owners of
the latter confirmed the proxy data
obtained from the US Internal Revenue
Service but the publishers of the former
two journals, the American Medical Asso-
ciation and the Massachusetts Medical
Society, did not respond.
Again, the authors cannot infer the
intentions of their nonrespondent editors.
Editors are proud of their independence
but independence goes only as far as an
owner permits, as we know from the sorry
history of dismissed editors of NEJM and
the Canadian Medical Association Journal,
amongst others.
Journals as Leaders: A Paradox
In many ways, JAMA has led the way in
promoting publishing integrity—including
its call for independent statistical analysis
of submitted industry-sponsored trials [9]
and its publication of best practice recom-
mendations for professional medical asso-
ciations [10]. The authors of the latter
paper, who include the journal’s editor-in-
chief, state: ‘‘Professional medical associa-
tions have a duty to bring to their
members the best scientific evidence on
the efficacy and suitability of drugs and
devices. These efforts must be separate
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tions.’’ It is a paradox that the professional
medical association that owns JAMA was
less than open and transparent with
Lundh and colleagues about potential
financial conflicts (such as their income
from industry sources) as they expect their
authors to be.
Stronger Guidance Needed
The various bodies that advise editors
may need to strengthen their guidance.
The Council of Science Editors’ White
Paper on Promoting Integrity in Scientific
Journal Publication [11] includes as a
potential conflict for editors ‘‘employment
by an organisation that would obtain some
advantage from a favourable product-
related publication.’’ The International
Committee of Medical Journal Editors
(ICMJE) states that editors who make the
final decisions about manuscripts must
have no ‘‘personal, professional or finan-
cial involvement in any of the issues they
might judge.’’ The Committee on Publi-
cation Ethics (COPE) code of conduct for
editors requires them to prevent business
needs from compromising important in-
tellectual standards. None of these organi-
sations comment on the potential conflicts
that might arise when a journal or
publisher receives a substantial proportion
of its income from reprints (23%, Massa-
chusetts Medical Society; 41%, The Lancet;
53%, American Medical Association).
Journal editors have expended much
time and effort in teasing out how to
handle authors’ and reviewers’ competing
interests. They need now to concentrate
on their own and those of their employers,
lest we reach the dismal scenario described
by Marcia Angell: ‘‘it is simply no longer
possible to believe much of the clinical
research that is published, or to rely on the
judgment of trusted physicians or author-
itative medical guidelines. I take no
pleasure in this conclusion, which I
reached slowly and reluctantly over my
two decades as an editor of The New
England Journal of Medicine’’ [12].
Author Contributions
ICMJE criteria for authorship read and met:
HM. Agree with the manuscript’s results and
conclusions: HM. Wrote the first draft of the
paper: HM.
References
1. Lundh A, Barbateskovic M, Hro ´bjartsson A,
Gøtzsche PC (2010) Conflicts of interest at
medical journals: The influence of industry-
supported randomised trials on the journal
impact factor. PLoS Med 7: e354. doi:10.1371/
journal.pmed.1000354.
2. Conen D, Torres J, Ridker PM (2008) Differential
citation rates of major cardiovascular clinical
trials according to source of funding: a survey
from 2000 to 2005. Circulation 118: 1321–1327.
3. Kulkarni AV, Busse JW, Shams I (2007) Charac-
teristics associated with citation rate of the medical
literature. PLoS ONE 2: e403. doi:10.1371/
journal.pone.0000403.
4. Bhaudari M, Busse J, Devereaux PJ, Montori VM,
Swiatkowski M, et al. (2007) Factors associated
with citation rates in the orthopaedic literature.
Can J Surg 50: 119–123.
5. Phillips DP, Kanter EJ, Bednarczyk B, Tastad PL
(1991) Importance of the lay press in the
transmission of medical knowledge to the scien-
tific community. N Eng J Med 325: 1180–1183.
6. Chapman S, Nguyen TN, White C (2006) Press-
released papers are more downloaded and cited.
Tob Control 16: 71.
7. Ross J, Hill KP, Egilman DS, Krumholz H (2008)
Guest authorship and ghost writing in publica-
tions related to Rofecoxib: a case study of industry
documents from Rofecoxib litigation. JAMA 299:
1800–1812.
8. Lexchin J, Bero LA, Djulbegovic B, Clark O
(2003) Pharmaceutical industry sponsorship and
research outcome and quality: a systematic
review. BMJ 326: 1167–1170.
9. Fontanarosa PB, Flanagin A, DeAngelis CD
(2005) Reporting conflicts of interest, financial
aspects of research, and role of sponsors in funded
studies. JAMA 294: 110–111.
10. Rothman DJ, McDonald WJ, Berkowitz CD,
Chimonas SC, DeAngelis CD, et al. (2009)
Professional medical associations and their rela-
tionships with industry: a proposal for controlling
conflict of interest. JAMA 301: 1367–1372.
11. Scott-LichterDandtheeditorial policycommittee,
Council of Science Editors. CSE’s white paper on
promoting integrity in scientific journal publica-




12. Angell M (January 15, 2009) Drug companies and
doctors: A story of corruption. The New York
Review of Books 56. Available: http://www.
nybooks.com/articles/archives/2009/jan/15/
drug-companies-doctorsa-story-of-corruption/.
Accessed 20 September 2010.
PLoS Medicine | www.plosmedicine.org 2 October 2010 | Volume 7 | Issue 10 | e1000355